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Abstract
Background: Forty percent of babies who are stillborn born die after 36 weeks gestation and have no lethal structural
abnormality. Maternal perception of reduced fetal movement (RFM) is associated with stillbirth and is related to abnormal
placental structure and function. The ultimate objective of this trial is to assess whether for women with RFM, intervention
directed by measurement of placental biochemical factors in addition to standard care improves pregnancy outcome
compared with standard care alone. This is the protocol for a pilot trial to determine the feasibility of a definitive trial and
also provide proof of concept that informing care by measurement of placental factors improves neonatal outcomes.
Methods: ReMIT-2 is a multicentre, pilot randomised controlled trial of care informed by results of an additional placental
factor blood test versus standard care alone for women presenting with RFM at or after 36+ 0 weeks gestation. Participants
will be randomised 1:1 to the intervention arm where the blood test result is revealed and acted on, or to the control arm
where the blood sample is not tested immediately and therefore the result cannot be acted on. All participants will be
followed up six weeks after delivery to assess their health status and views of the trial, along with healthcare
costs. A sub-group will be interviewed within 16 weeks after delivery to further explore their views of the trial.
Outcomes to determine feasibility of a definitive trial include number of potentially eligible women, proportion
lost to follow-up, clinical characteristics at randomisation, reasons for non-recruitment, compliance with the trial
intervention and views of participants and clinicians about the trial. Proof of concept outcomes include: rates of
induction of labour; Caesarean birth; and a composite neonatal outcome of stillbirths and deaths before discharge,
5-min Apgar score < 7, umbilical artery pH < 7.05 and admission to neonatal unit for > 48 h.
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Discussion: Results from this pilot trial will help determine whether a large definitive trial is feasible. Such a study
would provide evidence to guide management of women with RFM and reduce stillbirths.
Trial registration: ISRCTN Registry, ISRCTN12067514. Registered on 8 September 2017.
Keywords: Reduced fetal movement, Placental biomarker, sFlt-1/PlGF ratio, Placenta, Maternal serum, Stillbirth,
Perinatal mortality, Feasibility
Background
In the UK, approximately 1 in 220 babies are stillborn,
which describes a baby born with no signs of life after
24 weeks of pregnancy [1]. The rate of stillbirth in the
UK ranks 24th out of 49 high-income countries and the
annual rate of reduction (ARR) is much lower than other
comparable nations; for example, from 2000 to 2015, the
ARR in the UK was 1.4% compared with 6.8% in the
Netherlands [2]. Forty percent of babies who are still-
born die after 36 weeks of pregnancy and have no lethal
structural abnormality [3]. If these babies could be iden-
tified and delivered earlier, lives could be saved with
minimal impact on neonatal services. As well as the loss
of life for the child, stillbirth is associated with signifi-
cant psychological and social consequences for parents
and the maternity staff who care for them, along with an
economic impact on healthcare services [4]. Thus, a re-
duction in stillbirth has the potential to save NHS re-
sources and reduce resultant financial costs. One means
to reduce stillbirth is to focus on improving care for
women at increased risk.
An association between maternal perception of re-
duced fetal movement (RFM) and stillbirth has been
documented for > 40 years [5, 6]. Suboptimal manage-
ment of RFM has been highlighted in two Confidential
Enquiries of antepartum stillbirths carried out in the UK
almost 20 years apart [7, 8]. Although there has been na-
tional guidance for the management of RFM since 2011
[9], there is significant variation in clinical practice be-
tween practitioners and maternity units, with a signifi-
cant proportion of women not receiving evidence-based
care [10–12]. This may, in part, be due to the lack of
high-quality evidence to direct the management of RFM
in late pregnancy [13]. This manuscript describes the
protocol for pilot randomised controlled trial of manage-
ment of RFM informed by a biochemical test; the proto-
col has been reported in accordance with the SPIRIT
checklist (Additional file 1).
Rationale for study population
Maternal perception of RFM is associated with increased
risk of stillbirth, fetal growth restriction (FGR), fetoma-
ternal haemorrhage and neurodevelopmental delay [14].
RFM is thought to be a symptom of nutrient and/or
oxygen restriction [15]. This is supported by observed
changes in placental structure and function compared to
women with normal fetal activity and the observation
that babies born following maternal perception of RFM
are relatively acidaemic compared to those with normal
fetal movements [16, 17]. Most studies estimate that
RFM increases the risk of stillbirth by two- to threefold
[14, 18]. Importantly, RFM is a common reason to
present to maternity services in the third trimester of
pregnancy with 6–15% of women presenting on at least
one occasion [19, 20]. Therefore, this trial focuses on
women with RFM as a frequently occurring symptom in
late pregnancy, which identifies a group of women at in-
creased risk of adverse outcome late in pregnancy.
The need for studies in this area was highlighted by
the paucity of evidence identified in a systematic review
of the management of RFM [13] and the Stillbirth Prior-
ity Setting Partnership, which identified two relevant pri-
orities [21]: (1) which investigations identify a fetus at
risk of stillbirth after a mother has experienced RFM;
and (2) how can the structure and function of the pla-
centa be assessed during pregnancy to detect potential
problems and reduce the risk of stillbirth?
Although RFM is associated with increased perinatal
morbidity and mortality, intervention by delivering infants
before 36 weeks gestation may increase perinatal mortality
as the neonatal mortality rate for singleton pregnancies
exceeds the stillbirth rate until 36 weeks gestation and
there is evidence of increased morbidity for births before
38 weeks gestation [22]. Therefore, this trial will examine
the potential benefit of assessing placental dysfunction
using a novel marker of placental structure and/or func-
tion in combination with delivery when indicated by that
marker at or after 36 weeks gestation.
Rationale for study design
This is a multicentre pilot trial to determine whether a
larger definitive trial of a placental biomarker to inform
the decision of whether or not to deliver a baby is
possible and provides evidence of proof of concept by
assessment of a composite measure of perinatal out-
come. The trial design was informed by a single-centre
feasibility study (ReMIT study, ISRCTN 07944306)
which randomised 120 women to management based on
cardiotocography (CTG), ultrasound scan and measure-
ment of human placental lactogen (hPL) versus standard
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care (CTG and ultrasound if indicated) [23]. This study
found that trial participation was associated with a decrease
in maternal anxiety and high levels of participant satisfac-
tion confirmed by a minimal loss to follow-up (< 2%).
Although the intervention was associated with an increase
in induction of labour for RFM, it was not associated with
an increased rate of instrumental vaginal deliveries or
Caesarean section. There was a reduction in the composite
adverse perinatal outcome (perinatal mortality, birthweight
< 10th centile, admission to neonatal intensive care unit
[NICU], umbilical artery pH < 7.1) from 29% in controls to
12% in the intervention group. These encouraging data
indicate that a larger trial is needed to evaluate the poten-
tial for this intervention to reduce stillbirth. However, to
address stillbirth or perinatal death as a primary outcome
would require a very large clinical trial. Assuming a rate of
stillbirth of 0.3% in women with RFM, > 82,000 women
would be required to detect a reduction in stillbirth of
one-third (i.e. to 0.2%) with 80% power and 110,000 with
90% power.
One alternative would be to address whether the inter-
vention prevents significant perinatal asphyxia detected
by perinatal death or fetal acidaemia at birth or admission
to the NICU for > 48 h. Similar approaches have recently
been employed by the INFANT [24] and DIGITAT studies
[25]. In the ReMIT feasibility study, this composite out-
come had a frequency of 6% [23]. To detect a 30% reduc-
tion to 4.2% would require 5000 women with 80% power
and 6500 women with 90% power. Such recruitment may
be possible using 30–40 sites over 24 months. To deter-
mine whether this is feasible, the ReMIT-2 pilot trial will
be conducted at approximately six sites over nine months
with an aim to recruit 175–225 eligible participants during
this time. The sites will vary in size (in terms of number of
births per year) to ensure that the data are representative
of the range of sites that would participate in the main
trial. ReMIT-2 will use the same composite primary out-
come measure as for the DIGITAT study. This pilot trial
has not been powered to detect a difference in this com-
posite perinatal outcome, but the individual components
will be measured to assess proof of concept.
In addition to assessing whether incorporating measure-
ment of a placental biomarker into the management of
RFM improves pregnancy outcome, information will also
be collected regarding participant and staff experiences of
the intervention through qualitative and quantitative mea-
sures. These data will provide important information re-
garding the feasibility and acceptability of the intervention
and will help to identify potential barriers, particularly in
relation to conducting a larger trial. The economic evalu-
ation will consider the resources required to implement
the evaluation, including healthcare costs and the costs to
families. The cost-effectiveness of the intervention will be
calculated.
Justification for choice of intervention and placental
biomarker
As women with RFM are at increased risk of adverse
pregnancy outcome, further tests are currently employed
after a woman presents with RFM to identify fetal
compromise using CTG, ultrasound assessment of fetal
biometry and liquor volume, and fetoplacental Doppler
studies [15]. However, this approach is based on
low-grade evidence and further studies are needed [13].
As RFM is associated with abnormalities of placental
structure and function [16], it was hypothesised that in-
clusion of placental biomarkers could improve identifica-
tion of pregnancies ending in an adverse outcome. In
recent years, interest in biochemical and sonographic
markers of placental dysfunction, such as measurement
of placental growth factor (PlGF) [26], hPL [27] and pla-
cental echotexture, has increased [28]. This is in part
due to studies reporting low levels of placental bio-
markers in placentally mediated pregnancy complica-
tions such as pre-eclampsia [29], FGR [30] and women
perceiving RFM [27]. Cohort studies suggest that PlGF
is able to differentiate between FGR secondary to pla-
cental insufficiency and constitutionally small for gesta-
tional age (SGA) fetuses, which would be advantageous
as FGR infants are thought to be those at greatest risk of
complications [26]. The levels of biochemical factors
such as PlGF and hPL could reflect placental function as
they are synthesised in the syncytiotrophoblast, the cell
layer primarily responsible for nutrient and oxygen
transport to the fetus. This hypothesis is supported by
the observation that hPL levels correlate with placental
size [27]. In a cohort study of 303 women with RFM, ad-
verse pregnancy outcome was associated with an abnor-
mal CTG, reduced fetal size, reduced liquor volume and
lower levels of hPL [27]. Ultrasound estimated fetal
weight predicted 20/67 (29.8%) infants with adverse
pregnancy outcomes and hPL predicted a further 24/67
(37.8%). Therefore, combining estimated fetal weight
and hPL identified a greater proportion of adverse preg-
nancy outcomes than ultrasound alone. A further study
of women with RFM (n = 300) found a similar effect
where addition of PlGF to standard ultrasound assess-
ment improved the prediction of adverse outcome, with
the area under the receiver operating characteristic
(ROC) curve for composite adverse outcome improving
from 0.75 (0.64–0.86) to 0.88 (0.80–0.95) and the sensi-
tivity for adverse outcome improved from 9% (95% con-
fidence interval [CI] 4–19%) to 38% (95% CI 21–57%)
[31]. These data suggest adding measurement of placen-
tal biochemical factors to standard investigation regimes
will increase the prediction of adverse outcome.
A systematic review of diagnostic test accuracy was
carried out to determine the optimal marker of placental
dysfunction from PlGF, hPL, oestriol and placental
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calcification (Heazell et al. submitted to Cochrane Data-
base of Systematic Reviews; [32]). The diagnostic accuracy
was compared to ultrasound biometry for the identifica-
tion of stillbirth and SGA infants. This review found few
high-quality studies which reported the combination of
ultrasound estimated fetal weight and a placental bio-
marker, which is what is intended in ReMIT-2. Estimated
fetal weight had the highest sensitivity for predicting an
SGA baby (0.45, 95% CI 0.31–0.59). hPL performed better
than oestriol or placental calcification with a summary
sensitivity for detection of an SGA infant of 0.40 (95% CI
0.26–0.56) and a summary specificity of 0.86 (95% CI
0.77–0.91) in 3377 pregnancies. Four studies reported the
ability of hPL to identify a pregnancy that would end in
stillbirth. The sensitivity lies in the range of 0.63–1.00 and
specificity of 0.56–0.86. There were three studies of PlGF
in the prediction of an SGA infant, these reported a sensi-
tivity in the range of 0.69–1.00 (592 pregnancies) and a
specificity of 0.33–0.75. For stillbirth, PlGF reported a sen-
sitivity of 0.88 and a specificity of 0.63 [32]. This suggests
that PlGF has a slightly better test performance than hPL.
Initial feasibility work has indicated that sites are either
unable to perform hPL testing due to it being a
time-intensive (up to 3 h) and resource-intensive test, or it
is not practical to supply results within 24 h. Since the
PlGF test is much quicker to perform and is not
labour-intensive, PlGF is proposed as the biomarker of
choice to assess placental function in ReMIT-2.
PlGF is bound in maternal blood by soluble-fms-like
tyrosine kinase 1 (sFlt-1); therefore, assays to quantify PlGF
measure either unbound PlGF or the ratio of sFlt-1 to
PlGF. Comparison of these assays revealed no difference in
their diagnostic performance [33]. The sFlt-1/PlGF ratio
will be used in ReMIT-2 as it is a commonly available test
in hospitals in the UK. An sFlt-1/PlGF ratio of ≥ 38 will be
used as the threshold to identify significant placental dys-
function as this level increases the likelihood of delivery in
women with suspected pre-eclampsia due to intervention
to prevent maternal or fetal complications [34]. Before
undertaking ReMIT-2, a diagnostic test accuracy study in
318 women presenting with RFM found that an sFlt-1/
PlGF ratio of ≥ 38 had a sensitivity of 0.20 and a specificity
of 0.88 to identify a composite adverse perinatal outcome
(perinatal death, birthweight < 5th centile, umbilical cord
pH < 7.1, admission to NICU for > 48 h; unpublished data).
This compared to other methods employed, including oli-
gohydramnios (sensitivity 0.12, specificity 0.85) or umbilical
artery Pulsatility Index > 95th centile (sensitivity 0.05, speci-
ficity 0.95) and potentially represents a modest improve-
ment in prognostic accuracy over ultrasound scan alone.
Justification for qualitative study
Although little is known about women’s decision-making
surrounding participating in clinical trials while pregnant,
few clinical trials evaluate participants’ experiences to in-
form future trial design. In a follow-up questionnaire study
conducted after the MAGPIE trial (a randomised controlled
trial of magnesium sulphate to prevent eclamptic seizures),
women were asked three questions to describe their experi-
ence of participating in the study [35]. Eighty percent of
women responded and, in general, women were happy fol-
lowing participation in the MAGPIE trial and would do so
again. Women made suggestions on how the trial may have
been improved such as the timing and content of the par-
ticipant information and wanting to know trial results.
However, one difference between the MAGPIE trial and
ReMIT-2 is that in MAGPIE, the main focus was maternal
health as the women were unwell at the time of recruit-
ment, whereas in ReMIT-2 the primary focus is on fetal
wellbeing. In addition, ReMIT-2 is a ‘test-treat’ study rather
than a trial of the effectiveness of an intervention. Thus, as-
sessment of mothers’ experience is important in this pilot
study as both of these differences may affect women’s per-
ceptions of randomisation and participating in the study.
A recent qualitative study of women presenting with
RFM demonstrated that presentation to the maternity
service is a considered decision and for some respon-
dents the prospect of intervention was a barrier to con-
sultation [36]. Women were concerned for their baby’s
wellbeing and sought investigation to confirm that their
baby was healthy. This study highlighted powerful influ-
ences on women’s behaviour following perception of
RFM. Thus, for future studies in this area, it is important
to understand how participating in a randomised trial af-
fects their experience of care. The Participant Views ques-
tionnaire being used in ReMIT-2 is adapted from that
used in a single-centre feasibility study which achieved a
69% response rate [23] and includes questions initially de-
scribed to evaluate the MAGPIE study [35].
As clinicians have a critical role in recruiting partici-
pants to clinical trials, their views and experiences will
be recorded in this pilot study. In many studies, aca-
demic clinicians who initiate clinical trials are frequently
not involved in recruiting participants. In their review of
a maternity trial that did not meet recruitment targets,
Costescu and Cullimore found that although all clini-
cians were able to identify eligible patients, only 60%
had invited parents to participate [37]. Clinicians cited
failure to consider trial participation and excessive clinical
workload as the most commonly cited barriers to recruit-
ment. They also identified a lack of personal incentive to
recruit patients as a significant barrier. Thus, further ex-
ploration of the views of clinicians is needed to inform a
definitive trial and for randomised controlled trials in ma-
ternity care as a whole.
Finally, it is important to gain further insight into how
acceptable the sFlt-1/PlGF test is given the performance
of this assay. Views will be gained from both women
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who do not consent to participate in the trial and those
who do consent, along with the opinions of clinicians.
The information obtained through this qualitative study
will be used to inform the design of the large main trial.
Objective
The overall objective of this trial is to assess whether for
women with RFM, intervention directed by measurement
of placental factors in addition to standard care improves
pregnancy outcome compare with standard care alone.
The aims of this pilot study are to determine whether a
large main trial would be feasible and to provide proof of
concept that informing care by measurement of the
sFlt-1/PlGF ratio may improve neonatal outcome.
Methods/Design
This is a multicentre, randomised controlled pilot trial of
standard care informed by the results of an additional pla-
cental factor blood test versus standard care in women
presenting with RFM at or after 36+ 0 weeks gestation.
Participants
The flow of each participant from presentation through to
follow-up is shown in Fig. 1. Inclusion criteria are women
Fig. 1 (See legend on next page.)
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presenting with RFM before the onset of labour between
36+ 0 and 41+ 0 weeks gestation (assessment of gestation
will be based on the best available information which will
usually be the first or dating scan); viable singleton preg-
nancy on initial assessment; no indication for immediate
delivery as assessed by CTG and ultrasound scan;
provision of written informed consent. Exclusion criteria
are maternal age < 16 years or > 50 years; fetus known to
have any congenital anomalies as per the Fetal Anomalies
Screening Programme (FASP) [38] or any other severe
structural abnormality. Other exclusion criteria are mul-
tiple pregnancy; women for whom it is their first attend-
ance to any antenatal care, e.g. ‘unbooked women’;
previous randomisation into the ReMIT-2 trial in this
pregnancy and concurrent participation in the interven-
tion phase of another clinical trial which determined the
timing or mode of delivery.
Trial intervention
All participants will have a blood sample taken to meas-
ure the sFlt-1/PlGF ratio and will be randomised 1:1 to
standard care with the blood sample tested locally at the
time and the results revealed and acted on (intervention
arm), or for the blood sample to be tested at a later time
by a central NHS laboratory so the result is not available
to site staff or the participant and therefore cannot be
acted on (control arm; Fig. 1). Participants in the interven-
tion arm with an sFlt-1/PlGF ratio ≥ 38 will be offered de-
livery at 37+ 0 weeks (or as soon as possible after 37 weeks)
by the most appropriate method and induction of labour
should commence within 48 h of this offer. Those in
the intervention arm with an sFlt-1/PlGF ratio < 38 or
those in the control arm will continue with usual care
[9]. Participants in both arms will be free to decline
the recommended management plan and may return
for any further episodes of RFM before delivery but
cannot be re-randomised into the trial.
Outcome measures
Outcomes for the pilot trial have been separated into
those that determine the feasibility of a definitive trial and
those that address whether the intervention might have an
effect on neonatal outcome or healthcare costs, i.e. proof
of concept. The feasibility outcomes are: number of poten-
tially eligible women at each site and number of women
recruited at each site; proportion lost to follow-up after
discharge from hospital and reasons for loss to follow-up;
spectrum of clinical characteristics of women at
randomisation (frequency of SGA fetuses, obstetric his-
tory, nulliparous); reasons for non-recruitment (including
views of women about reasons for not participating col-
lected at point trial is offered via an anonymous survey
and a short interview); compliance with the trial interven-
tions and reasons for non-compliance; completeness of
data collection for planned outcomes in the main trial;
participants’ views on the sFlt-1/PlGF test; views of
women about participation collected after birth using
a Participant Views questionnaire (modified from that
used in the single-centre feasibility study [23]) and
via an optional Midwife-Led Interview; views of clini-
cians on the sFlt-1/PlGF test performance, trial processes
and interventions collected using a Health Professional
Views questionnaire. The proof of concept outcomes for
the mother are: frequency of induction of labour or
planned Caesarean and reasons for these procedures; fre-
quency of maternal hypertensive disorders defined as de-
velopment of gestational hypertension or pre-eclampsia;
maternal deaths before discharge or admissions to the in-
tensive care unit (ICU); and change in the Generalised
Anxiety Disorder 2 (GAD-2) scale [39]. For the baby. the
proof of concept outcomes are: stillbirths and deaths be-
fore discharge; 5-min Apgar score of < 7; umbilical artery
pH < 7.05; admission to the neonatal unit for > 48 h; SGA
(< 10th centile on neonatal birthweight standards [40–
42]); use of therapeutic cooling; length of stay in hospital;
duration of respiratory support; and number of depend-
ency days on the neonatal unit. The impact on quality of
life and resource use will be assessed by the SF-12™
Health Survey [43], a Health Resource Use question-
naire and the diagnostic performance of the placental
factor test in participants allocated to the control arm
of the trial.
Sample size and recruitment
As this is a feasibility trial, a formal sample size for estimat-
ing between-group effects is not appropriate. ReMIT-2 will
recruit over a period of nine months from approximately
six UK sites and it is expected that 175–225 participants
will be recruited during this time. This number will give es-
timated margins of error (half width of 95% CI) for the pro-
portion recruited of approximately 5% and for the
proportion lost to follow-up after discharge of approxi-
mately 7.5%.
The maximum length of time from enrolment to deliv-
ery is six weeks. For participants not involved in the
(See figure on previous page.)
Fig. 1 Participant flow from presentation to follow-up. 1Participants in the control arm will have an extra blood sample taken to measure the
sFlt-1/PlGF ratio but the sample will not be tested immediately so the result will not be available to site staff or the participant and therefore
cannot be acted on. 2Discuss care being offered. Participants can decline or request delivery irrespective of the sFlt-1/PlGF result or the group
they are randomised to
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Midwife-Led Interview, the follow-up period from
delivery to completion of the participant questionnaires
is ~ 10 weeks. For the sub-group of participants involved
in the Midwife-Led Interview, the follow-up period from
delivery to completion of the interview is ~ 16 weeks.
Enrolment and consent
As shown in Fig. 1, women presenting with RFM for the
first time at or after 36+ 0 weeks gestation will have a
pre-trial CTG to exclude fetal compromise along with
an ultrasound scan for fetal biometry, liquor volume and
umbilical artery Doppler. Once these investigations have
been confirmed as normal and all eligibility criteria are
met, written informed consent will be obtained. During
the consent process, a Participant Information Sheet will
be given along with a verbal explanation of the trial and
standardised information on the test performance of the
sFlt-1/PlGF assay in a visual format, e.g. DVD, YouTube,
transcript, etc. (Additional file 2). The trial intervention
means that ideally women need to be randomised on the
same day that they present with RFM (or within the next
working day); however, they will have the opportunity to
ask questions and discuss their participation with others
outside of the site research team. Although this is a lim-
ited timeframe, women in a prior feasibility study said that
they felt the timing of the approach to offer participation
was acceptable and that they had sufficient time to make a
decision whether to participate [23]. Separate optional
consent will be required for any participants who are in-
terested in taking part in the Midwife-Led Interview.
Women who decline to take part will be asked if they
are willing to complete an anonymous survey about their
reasons for not participating in the trial (Fig. 2). At the
Chief Investigator (CI) site only, this sub-group will also
be asked if they are willing to have a short interview to
further explore their reasons for not participating (Fig. 2).
A separate Short Interview Consent Form will be com-
pleted before this interview is conducted. These interviews
will last around 20 min and will be semi-structured using
an Interview Guide but participants will be encouraged to
speak openly and freely.
Randomisation
Eligible participants will be randomised in a 1:1 ratio
to either the intervention arm or the control arm.
Randomisation will be stratified by site and number
of weeks gestation when the participant first presents
at hospital (< 40 weeks gestation or ≥ 40 weeks of ges-
tation). The randomisation schedule is based on a
computer-generated pseudo-random code using ran-
dom permuted blocks of randomly varying size, cre-
ated by the Nottingham Clinical Trials Unit (NCTU)
in accordance with their standard operating procedure
(SOP) and held on a secure University of Nottingham
server.
Fig. 2 Flow for women not giving consent to the trial
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Investigators and delegated site staff will randomise
the participant using an online randomisation system via
a secure website developed and maintained by NCTU. It
is not possible to blind participants or site staff to the al-
located arm since those randomised to the intervention
arm will have the sFlt-1/PlGF ratio blood sample tested
at the time and their results revealed to inform the next
steps of their management plan. If a participant returns
for a further episode of RFM, they will be treated ac-
cording to standard care irrespective of the trial arm
they were randomised to and will not have any further
blood samples taken to measure the sFlt-1/PlGF ratio.
Trial assessments and procedures
All assessments and procedures to be performed at each
time point for participants are indicated in Fig. 3. Most
assessments will be done at the time of enrolment and
randomisation into the trial, including the SF12™ Health
Survey and GAD-2 scale, demographics, medical history,
concomitant medications, reasons for trial participation,
physical examination, urinalysis and blood sample for
the sFlt-1/PlGF ratio test. Further assessments will take
place after delivery and before discharge from hospital
including outcomes and defined serious adverse events
(SAEs), demographics for the baby, Apgar scores, umbil-
ical cord pH and base excess, neonatal unit admissions
and details of any respiratory support. Participants will
be followed up around six weeks after delivery via a
Postnatal Questionnaire consisting of the SF12™ Health
Survey, GAD-2 scale, Participant Views on the trial and
Health Resource Use details. In addition, those partici-
pants that have given consent will be contacted for an
optional Midwife-Led Interview.
Before recruiting their first participant, staff at sites
will be asked to complete part 1 of an online Health Pro-
fessional Views questionnaire regarding the test perform-
ance of the sFlt-1/PlGF assays. Before closing recruitment,
site staff will be asked to complete part 2 of the online
Health Professional Views questionnaire regarding their
experiences of the trial.
Adverse event reporting
Acting on the sFlt-1/PlGF ratio result is the intervention
being evaluated and thus adverse events (AEs) are out-
comes for the trial. Although stillbirths and deaths be-
fore discharge are outcomes for both the baby and the
participant, these will still be considered as SAEs and
will be reported as such.
Central analysis of sFlt-1/PlGF ratio blood samples
Aliquots of all blood samples taken from both the inter-
vention and control arms will be sent to an NHS labora-
tory at Manchester. This is to allow central analysis of
all samples to provide a measure of reliability for the
sFlt-1/PlGF ratio test. In addition, these samples will also
be analysed for hPL as another candidate biomarker of
placental dysfunction to compare the diagnostic accur-
acy of hPL versus the sFlt-1/PlGF ratio test.
Data management
All trial data will be entered on a trial specific database
through the electronic Case Report Form (eCRF) with
participants identified only by their unique trial number
and initials. The database will be developed and main-
tained by NCTU. Access to the database will be re-
stricted and secure. Any missing or ambiguous data will
be queried with the site via the eCRF for prompt reso-
lution. For the follow-up of participants at six weeks
after delivery and the Midwife-Led Interviews, identifi-
able information about participants will be entered by
the sites into the online randomisation system. This in-
formation will be held in a separate database to the trial
anonymised data. Access to this information will be re-
stricted to those involved in the follow-up phase, as
authorised by the CI.
Statistical analysis
A Statistical Analysis Plan will be agreed before database
lock and release of the intervention allocations. Report-
ing of the trial will be in accordance with Consolidated
Standards of Reporting Trials (CONSORT) guidelines.
All outcomes will be summarised using appropriate
descriptive statistics. Continuous variables will be sum-
marised in terms of the mean, standard deviation,
median, lower and upper quartiles, minimum, maximum
and number of observations. Categorical variables will
be summarised in terms of frequency counts and
percentages. Data summaries will be presented accord-
ing to allocated arm, regardless of compliance with the
intervention. Comparisons may be made between the
intervention arms but formal statistical testing will not
be performed since this is a feasibility trial. Where ap-
propriate, differences between arms will be presented
with 95% CIs.
The number of potentially eligible women and the
number of women randomised at each site will be de-
scribed using standard summary statistics. Where rea-
sons for non-recruitment are available, these will also be
summarised. The proportion of women lost to follow-up
after discharge from hospital will be summarised as a
proportion of the total number randomised, and where
available, reasons for loss to follow-up will be sum-
marised. The proportion lost to follow-up in each arm
will be visually inspected to determine whether there ap-
pears to be a difference between the arms. No formal
statistical testing will be performed.
The number of women who had their blood sample
analysed, sFlt-1/PIGF ratio obtained and test result
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revealed will be summarised by trial arm. If the care
pathway offered to the women deviates from the path-
way indicated by their allocation, then the reasons for
this deviation will be summarised. The pathway indi-
cated by the sFlt-1/PlGF ratio blood test results for
women in the control arm will be compared to the path-
way they were actually offered to determine whether the
sFlt-1/PlGF ratio results would have made any difference
to the treatment pathway they were offered.
The clinical characteristics of the women will be
summarised overall and by intervention arm using ap-
propriate summary statistics. Neonatal outcome will be
summarised by intervention arm both separately and as
a composite measure using counts and proportions.
The type of births women had will be summarised for
each arm using counts and proportions. Length of stay
in the maternity unit will be summarised using me-
dians. Maternal morbidity will be summarised as the
proportion of women developing gestational hyperten-
sion or pre-eclampsia. Anxiety measured by the GAD-2
scale at enrolment and ~ 6 weeks after birth, and the
change in score between these points, will be sum-
marised using appropriate summary statistics.
Further information, including details of additional in-
vestigations, data derivations (where appropriate) and
methods to address missing data, will be documented in
the Statistical Analysis Plan. Statistical investigation of
subgroups is not planned. However, some outcomes may
be summarised according to parity and gestation when
the woman first presents. This will be detailed in the
Statistical Analysis Plan.
Midwife-Led Interviews
Midwife-Led Interviews will be performed in a sub-group
of participants ~ 16 weeks after delivery. To ensure that a
meaningful exploration can be made between different
women’s experiences of the trial, participants will be pur-
posefully sampled based on their response to the question
asking if they would agree to participate in the ReMIT-2
trial again in the Participant Views Questionnaire. A form
of theoretical sampling known as maximum variation
sampling [44] will be used. Participants will be allocated
to one of eight groups using a planned sampling matrix
(Fig. 4). This matrix acknowledges that participants’
perceptions of the trial could be altered by the arm they
were randomised to (intervention or control) and the out-
come for the participant or the baby.
A Research Midwife will interview up to five participants
from each of the eight groups using a semi-structured
interview guide. Interviews will be audio recorded and tran-
scribed. Qualitative data will be analysed using framework
analysis, which focuses on identifying and giving mean-
ing to patterns within the data set [45]. Such thematic
analysis is independent of any particular theoretical
framework and can be applied across a broad range of
research questions [46]. Analysis will be performed in
six recursive phases [47] by members of the research
team to increase trustworthiness. Established methods will
be used to integrate data from separate mixed-methods
studies [48].
Health economic analyses
If the information obtained from an additional test of pla-
cental function either reduces the frequency of adverse
pregnancy outcomes or leads to more obstetric interven-
tion such as induction of labour or Caesarean births, then
this will have important cost implications that would need
to be assessed in a larger definitive trial. For the current
pilot trial, the feasibility of collecting the appropriate in-
formation to inform a future trial will be explored and
data to be targeted can also be assessed. As a result of the
data collected in the pilot trial, a preliminary model based
economic evaluation will be undertaken.
This evaluation will use data obtained from the sys-
tematic review and meta-analyses of diagnostic accuracy
and interventions supplemented by information on costs
and resource use in this trial. The clinical pathways that
women’s care will follow will be mapped out. Relevant
data on the cost of intervention and resource use will be
obtained from the eCRF, a Health Resource Use ques-
tionnaire and the SF12™ Health Survey [43]. Unit costs
will be applied to the resource use from standard pub-
lished sources such as those from Personal Social Ser-
vices Research Unit (PSSRU) [49]. Data obtained from
the SF-12™ Health Survey will be used to calculate differ-
ences in these two scores between the two different
intervention arms in the trial. The results of the analysis
will be reported in terms of incremental cost per poor
pregnancy outcome (as described for the primary
(See figure on previous page.)
Fig. 3 Summary of assessments. aFor stillbirths or deaths, the SF-12™, GAD-2, Health Resource Use and Participant Views questionnaires are only
sent where the participant has confirmed they wish to continue in the trial. bMidwife-Led Interviews are only to take place if the baby is still alive at
the time of the interview, or for stillbirths and deaths where the participant has confirmed they wish to continue in the trial. csFlt-1/PlGF ratio blood
test results will only be available at the time for participants in the intervention arm, not those in the control arm. dFor stillbirths and neonatal deaths
prior to discharge, record cause of death, post-mortem findings and placental histology. Defined SAEs must be recorded from delivery to discharge
from hospital for both the baby and participant. eDemographics e.g. gender, birthweight etc. fApgar scores to be recorded at 1 minute and 5 minutes
after birth. gFor neonatal unit admissions, record reason for admission, duration of admission and number of dependency days
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outcome of the study) avoided and incremental cost per
quality-adjusted life year (QALY).
The results of these economic analyses will be
presented using cost-effectiveness acceptability curves to
reflect sampling variation and uncertainties in the
appropriate threshold cost-effectiveness value. Most spe-
cifically the results of this model will provide important
information to target for any future definitive trial.
Trial governance
The Trial Management Group (TMG) consists of the CI,
Trial Statistician, Trial Manager and Senior Trial Man-
ager. The TMG is responsible for the day-to-day manage-
ment of the trial, including review of protocol deviations
entered into the eCRF, and reporting to an independ-
ent Trial Steering Committee (TSC). Since the risk of
adverse outcomes is deemed very low in this trial, a
separate Data Monitoring Committee (DMC) has not
been convened and therefore the TSC will also assume
DMC responsibilities such as monitoring safety data and
reviewing protocol deviations.
Discussion
The results from this trial will be used to determine
whether a larger definitive trial of a placental biomarker
to inform the decision of whether to deliver a baby is
possible. It will also provide evidence of proof of concept
by assessment of a composite measure of perinatal out-
come. In addition, data regarding the cost and accept-
ability of this type of intervention will be generated,
which are essential components in determining the feasi-
bility of a definitive trial.
High quality research is urgently needed to help re-
duce the rate of stillbirth in the UK; while RFM is asso-
ciated with stillbirth in multiple observational studies,
there is a paucity of data from interventional trials to in-
form clinical management. Such research will address
some of the priorities identified in the Stillbirth Priority
Setting Partnership [21] and will help to further develop
guidance on management of RFM in late pregnancy.
Trial status
Protocol version 2.0 9 January 2018. Recruitment opened
on 12 March 2018 and is expected to continue to the
end of December 2018.
Additional files
Additional file 1: SPIRIT 2013 Checklist: recommended items to address
in a clinical trial protocol and related documents. (PDF 187 kb)
Additional file 2: ReMIT-2 Participant Information Video MP4.
(MP4 175104 kb)
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